Sharekhan's research report on Ipca Laboratories
Ipca’s domestic formulations that account for around 45% of the overall topline of the company is on a strong footing to report double digit growth over the next two years. Ipca’s API business is also witnessing strong demand traction, which is expected to sustain going ahead. Strong revenue growth supported by easing capacity constraints augurs well for Ipca from a growth perspective. Ipca’s stock price has corrected by ~17%, thus providing a good entry point for investors.
Outlook
We maintain Buy recommendation on the stock of IPCA Laboratories Limited (Ipca) with an unchanged PT of Rs. 2,560.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
